Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases. Here, we report a mouse sarcoma model expressing SS18-SSX1, complementing our prior model expressing SS18-SSX2. Exome sequencing identified no recurrent secondary mutations in tumors of either genotype. Most of the few mutations identified in single tumors were present in genes that were minimally or not expressed in any of the tumors. Chromosome 6, either entirely or around the fusion gene expression locus, demonstrated a copy number gain in a majority of tumors of both genotypes. Thus, by fusion oncogene coding sequence alone, SS18-SSX1 and SS18-SSX2 can each drive comparable synovial sarcomagenesis, independent from other genetic drivers. SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences overall. In direct tumorigenesis comparisons, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1, but equivalent in its generation of biphasic histologic features. Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18-SSX2 tumors. Re-analysis of human SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 expression in SS18-SSX1 tumors. This suggests that the translocated locus may drive genotypephenotype differences more than the coding sequence of the fusion gene created. Two possible roles for native SSX2 in synovial sarcomagenesis are explored. Thus, even specific partial failures of mouse genetic modeling can be instructive to human tumor biology.
INTRODUCTION
Synovial sarcoma is the most common soft-tissue sarcoma in young adults and adolescents. 1 Although more responsive to cytotoxic chemotherapy than some other sarcomas, synovial sarcoma proves to be ultimately resistant to most therapies and is usually fatal after metastasis. Synovial sarcoma cells have been shown consistently to bear a balanced t(X;18) chromosomal translocation 2 that generates a fusion between SS18 (formerly called SYT) and an SSX gene. 3 Almost the entire SS18 coding sequence is included in each fusion, whereas only the final 78 amino acids of SSX1 or SSX2 are included 4, 5 By sequence analysis, members of the SSX gene family are projected to be transcriptional repressors ( Supplementary  Figure 1) ; their expression is limited to the testis and a few cancers; and little more is known about them beyond their involvement in synovial sarcoma fusions. [6] [7] [8] SS18 has been shown to be a member of the mammalian SWI/SNF complex. 9, 10 Epigenetic mechanisms have been described wherein SS18-SSX fusion oncoproteins serve as master regulators of transcription in synovial sarcoma cell lines. 10, 11 These mechanisms led to the hypothesis that SS18-SSX fusion genes were singular driving genetic events in synovial sarcomagenesis. 12 This hypothesis has been supported by limited comparative genomic hybridization and sequencing data that identified few copy number variations and mutations in most synovial sarcomas. [13] [14] [15] SS18-SSX2 expression in certain cell lineages proved to be sufficient to drive synovial sarcomagenesis in the mouse at 100% penetrance. 16, 17 This was initially accepted as circumstantial proof that few or no other genetic changes were necessary for transformation. However, direct comparisons with two other sarcomagenic fusion oncogenes, EWSR1-ATF1 and ASPSCR1-TFE3 (related to clear cell and alveolar soft part sarcoma, respectively) demonstrated that SS18-SSX2 generated fewer sarcomas at longer latencies. 18, 19 This suggested that SS18-SSX2-driven sarcomagenesis may require some secondary genetic hit or that the fusion itself was simply less oncogenic. This redirected attention toward SS18-SSX1.
Early clinical series comparing SS18-SSX1 to SS18-SSX2 found the former to be more common and to associate with higher stage at presentation and worse prognosis. [20] [21] [22] [23] [24] Some subsequent series contradict this claim and a recent meta-analysis found no strong statistical evidence for it, 25 but the possibility of differential sarcomagenic potential was directly testable in the mouse.
RESULTS
Comparable conditional mouse alleles of SS18-SSX1 and SS18-SSX2 expression To investigate its oncogenic potential, we generated a mouse allele that conditionally expressed the SS18-SSX1 complementary DNA (cDNA) from the Rosa26 locus (termed hSS1; Figure 1a ). Using identical primers to capture the full-length coding sequence and early 3' untranslated region, this hSS1 allele matched the previously described allele for SS18-SSX2 (herein termed hSS2). 16 Mouse embryonic fibroblasts isolated from each model and exposed in culture to TATCre expressed their respective fusion genes ( Figure 1b ) and underwent apoptosis ( Figure 1c ). Similarly, both hSS1 and hSS2 disrupted early embryogenesis following expression induced by Hprt-Cre ( Figure 1d ). Thus, hSS1 and hSS2 were similarly conditional and toxic to cells in most contexts.
SS18-SSX1 expression in mesenchymal progenitors drives synovial sarcomagenesis Similar to prior reports with hSS2, 16 mice were bred to activate hSS1 in the Myf5-Cre lineage. Tumors arose in full penetrance and expressed the fusion gene, as evidenced by fluorescence because of green fluorescent protein expression from an internal ribosomal entry site on the targeted construct (Figures 1a and e ).
Synovial sarcomas are subclassified histologically as monophasic synovial sarcoma (MSS), which lacks areas of epithelial differentiation, or biphasic synovial sarcoma (BSS), which contains both fibrous/mesenchymal and epithelial areas. Comparable both to human synovial sarcomas and to hSS2 mouse tumors, hSS1driven tumors had both histologic types represented ( Figure 1f ). As BSS histology indicates a fundamental reprogramming of germ-layer cellular identities from mesenchymal origin to mucinous glandular structure formation, this is considered a diagnostic hallmark unique to synovial sarcoma. Finally, hSS1 tumors demonstrated the typical immunohistochemical staining with nuclear TLE1, cytoplasmic BCL2, and patchy epithelial membrane antigen and pancytokeratin ( Figure 1g ). SS18-SSX1 is therefore also a fusion oncogene capable of driving synovial sarcomagenesis in the mouse.
Synovial sarcoma exomes have few somatic mutations, none recurrent by fusion type
In order to test the genetic independence of each fusion oncogene, we sequenced Myf5-Cre-initiated tumor exomes for secondary mutations and compared them with germline control exomes. Few somatic mutations were identified (Figure 2 , Supplementary Tables 1 and 2) . Targeted, deeper sequencing was used for validation of all mutations that had an allelic fraction of at least 10% in the tumor and no more than a single read in the germline control tissue. Most identified mutations demonstrated variant allele fractions well below 40%, which in light of the 485% typical histologically determined tumor cell density in the samples, suggests that the mutations were subclonal across the neoplasm and therefore had not contributed to initial malignant transformation.
Transcriptome sequencing demonstrated that most mutations also arose in genes that were minimally expressed in the mutated allele-bearing tumor and minimally expressed in the other tumors that lacked the mutation. This supports their role as likely passenger mutations. Mutant transcript reads were only present as a large fraction of the reads that crossed the mutation site in genes that were minimally expressed overall. Notably, comparison of hSS1-and hSS2-induced tumors found a slight increase in the number of these passenger mutations in the former, which also developed and were harvested at an older age (mean 262 versus 168 days).
Mouse synovial sarcomas frequently amplify the fusion expression locus Exome sequencing was also analyzed to determine copy number variation across the genome. The only repeated copy number variation was in mouse chromosome 6, which was amplified either completely as a trisomy or partially in 24 of the 29 tumors ( Figures 3a and b ). The portion of chromosome 6 that was amplified always included the Rosa26 locus (Figures 3a and b ). PCR was used to test eight samples with noted amplification and found that the targeted allele, from which the fusion was expressed, was amplified in every case relative to the wild-type allele ( Figure 3c ). Comparative genomic hybridization was performed on an additional 11 tumors of the hSS2 genotype, from three different mice, showing the same trisomy of chromosome 6 in 7 of the tumors (Supplementary Figure 2) , with no other consistent changes. Thus, the only genetic change that frequently contributes to mouse synovial sarcomagenesis is amplification of part or all of chromosome 6, consistently including the fusion gene expression locus.
Synovial sarcoma transcriptomes do not consistently differ by fusion genotype
In order to achieve a detailed molecular comparison of synovial sarcomas driven by each fusion genotype, we compared transcriptomes (RNAseq) for tumors of each genotype initiated by Myf5-Cre. Unsupervised hierarchical clustering yielded some intermingling of hSS1 and hSS2 tumors ( Figure 4a ). Just over 1000 genes were differentially expressed between the two tumor genotypes at the P o 0.05 significance and twofold change threshold (Supplementary Table 3 ). As a validation cohort, transcriptomes from six tumors initiated by TATCre injection into the hindlimb (three of each fusion genotype) were also sequenced, with 152 genes differentially expressed to the same degree (Figure 4b , Supplementary Table 4 ). Only 18 genes were found to be shared as differentially expressed to the same degree and direction in both comparisons (Figures 4c-e ).
Comparable oncogenesis from SS18-SSX1 and SS18-SSX2 in the mouse To directly compare their oncogenic potential, we developed comparative mouse cohorts of hSS1 and hSS2, each induced by Myf5-Cre, Rosa26-CreER or hindlimb injection of the protein TATCre. 16, 17, 26 In each induction model, hSS1 expression resulted in slightly fewer, but comparably located tumors, at longer latencies (Figures 5a-c).
In the Myf5-Cre-induced mice, smaller tumors in both genotypes were MSS and rarely included epithelial areas. The Myf5-Cre;hSS2 mice more often had smaller, secondary tumors identified following killing prompted by a larger tumor, rendering a nonsignificant decrease in BSS prevalence in that group, overall (P = 0.33, Fisher's exact test; Figure 5d ). Analysis following stratification of tumors by size found equivalent prevalence of BSS histology in tumors 41 cm, irrespective of fusion genotype ( Figure 5d ). The prevalence of BSS histology in tumors initiated by Rosa26-CreER and TATCre injection was also not significantly different (P = 1.0 and P = 0.58, respectively; Figure 5d ).
Re-analysis of human synovial sarcomas identifies two genotype-phenotype correlations
Early human patient series correlated the SS18-SSX1 fusion genotype with worse prognosis. Some subsequent series have cast doubt on this. A meta-analysis found the impact to be subtle and not statistically significant. The prevalence of each fusion genotype has also varied somewhat between series.
To focus more clearly on differences associated with each fusion genotype, we retrieved raw data from 1181 patients in 17 of the largest clinical series of human synovial sarcomas in which the fusion type was identified by reverse transcriptase polymerase chain reaction (RT-PCR). Gender data were available from 1036 patients in 12 of the studies. The typical sarcoma male to female ratio of approximately 1.2:1 was reflected among SS18-SSX1expressing tumors pooled from the available series (Table 1) . A 41.4-fold shift in gender prevalence was apparent in SS18-SSX2expressing tumors ( Table 1 ). There are significantly fewer males with SS18-SSX2 tumors than SS18-SSX1 tumors.
Some clinical series of human synovial sarcomas have reported more rare BSS histology in SS18-SSX2 tumors, compared with SS18-SSX1 tumors. 21, 22, 27 We compared the prevalence of BSS histology in each fusion genotype across the assembled 17 series. This demonstrated a statistically significant reduction in BSS histology cases in synovial sarcomas of the SS18-SSX2 fusion genotype (P o 0.0001, Fisher's exact test; Supplementary Table 5 ).
BSS histology in the SS18-SSX2 fusion genotype was also tested for gender association. The ratio of male to female biphasic tumors among those expressing SS18-SSX1 was 1.6-fold higher than the ratio among tumors expressing SS18-SSX2 (Supplementary Table 6 ). Four series, including the largest, reported zero male patients with SS18-SSX2 BSSs.
These data pointed toward two genotype-phenotype relationships in human tumors that were not recapitulated in the mouse, reduced prevalence of male hosts to and BSS histology in SS18-SSX2 tumors.
Human SS18-SSX2 synovial sarcomas have reduced native SSX gene expression To identify transcriptional differences between human tumors of each fusion genotype that were not represented in the mouse tumor genotype-expression profile comparisons, we re-analyzed two patient series with reported microarray expression data. To avoid histologic bias, we limited initial comparisons with the pretreatment MSS tumor samples in each cohort. Few genes had significant differential expression (with matched direction of change) between SS18-SSX1 and SS18-SSX2 tumors in both cohorts (Figure 6a ). When these were cross-referenced to a third group of human samples (a relapsed tumors group from one of the two series), very few genes were significantly different in all three comparisons (Figures 6a and b ). None of these correlated with the genes identified from the mouse comparisons. In particular, the SSX genes were prominently represented in the human comparisons, all more highly expressed in SS18-SSX1 tumors.
We designed RT-quantitative PCR (qPCR) primer sets that targeted the 5' end of either SSX1 or SSX2, portions not included in the respective fusion transcripts. This RT-qPCR analysis of expression in a panel of human synovial sarcomas demonstrated that tumors almost universally expressed native SSX2, but detectably expressed SSX1 in only about half of tumors (Figure 6c ). The only tumor with negligible native SSX2 expression was the single male case of an SS18-SSX2-expressing MSS. The only tumor with higher SSX1 expression than SSX2 expression was in a female and was also driven by SS18-SSX2. SSX2 trended toward higher expression in SS18-SSX1 tumors (Figure 6d ).
This discrepancy in SSX gene expression between SS18-SSX1 and SS18-SSX2 human tumors was not recapitulated in mouse tumors. Expression of the known members of the homologous mouse Ssx gene family were not different between tumors of the two genotypes by RT-qPCR ( Supplementary Figure 3a) . In the mice, however, the fusion genes were expressed from cDNAs in the Rosa26 locus, which did not include structural rearrangements of the Ssx gene cluster on the X chromosome ( Supplementary  Figure 3b ). Human synovial sarcomas therefore have two important differences between the translocations that generate the SS18-SSX1 and SS18-SSX2 fusion genotypes. First, the t(X;18) translocation in a human synovial sarcoma disrupts one allele of the involved, native SSX gene, whose 3' exons it repurposes in the fusion gene. This could be especially impactful in males, in which the fusion disrupts the only copy of the involved SSX gene. Second, because SSX2 is oriented away from all the other SSX genes, translocation to SSX2 does not bring any of the other native SSX genes into the area of influence of any regional chromatin effects of the high expression SS18 locus ( Supplementary  Figure 3c ). This contrasts sharply to translocations in SSX1, which places most of the SSX genes, and SSX2 in particular, downstream and in close proximity to SS18.
Possible roles for native SSX2 in synovial sarcoma The model systems for in vitro glandular differentiation of human synovial sarcoma cells are not developed yet and the mouse SSX gene family homology to humans is not gene specific enough to test BSS histology or basic tumorigenesis dependence on SSX2 in vivo. We are therefore left to only hypothesis-generating experiments to explain a role for the loss of native SSX2 in either reduced synovial sarcomas in males or reduced BSS histology.
Knock-down of SSX2 expression by small interfering RNA in human synovial sarcoma cell lines hampered proliferation compared with a non-target control small interfering RNA (Figures 7a-e ). Proliferation increased upon introduction of an SSX2 overexpression vector compared with control conditions (Figures 7d and e ). These data suggest that SSX2 may function as a contributing oncogene in synovial sarcoma.
Analysis of three cohorts of human synovial sarcomas, comparing BSS with MSS tumors in each, identified very few genes with consistent differential expression ( Figure 7f ). The most significant among these was the RAB3IP gene (Figure 7g ), which encodes one of only two proteins known to interact with SSX2 specifically. The interaction domain is not included in the portion of SSX2 fused to SS18 in the fusion oncoprotein.
DISCUSSION
We report a new model of synovial sarcomagenesis in the mouse, driven by conditional expression of SS18-SSX1, complementing our former SS18-SSX2 model. 16 Exome sequencing demonstrated a striking absence of mutations that by allele fraction and gene transcription levels likely contributed to synovial sarcomagenesis. Although many mouse models of cancer demonstrate lower mutational burdens than their human counterparts, these mouse synovial sarcomas had particularly low mutation numbers per tumor. [28] [29] [30] [31] [32] [33] [34] The only recurrent genetic change in tumors, beyond the activation of the hSS1 or hSS2 fusion gene, was amplification of part or all of chromosome 6. Mouse tumors more frequently than human tumors demonstrate whole chromosome gains and losses. 35, 36 Although chromosome 6 trisomy may impact many genes, the partial chromosomal gains always included the Rosa26 locus and every copy number gain was an increase in the targeted allele. This indicates that increased expression of the fusion may contribute to oncogenesis. The increased expression by copy number gain is likely an artifact of expression from other than the native Ss18 locus. Indeed, the fact that one Ss18 allele is not disrupted by translocation may even emphasize the importance of increased expression of the fusion in the mice. The SS18-SSX fusion oncoprotein has been shown to compete with native SS18 for participation in the SWI/SNF complex. 10 The mouse tumors must express enough of the fusion to out-compete two functional alleles of native Ss18.
These data suggest that mutations beyond activation and possible amplification of the fusion oncogene are not strictly necessary to enable synovial sarcomagenesis in the appropriate cell of origin in the mouse. Beyond the t(X;18) chromosomal translocation, additional genetic derangements that have been identified in a minority of human synovial sarcomas 13, 15 may contribute to tumor progression or make up for a less than ideal cell of origin.
As SS18-SSX fusion oncogenes are capable of driving synovial sarcomagenesis independently, the details of each fusion genotype and differences between them may engender significant phenotypic differences in tumors. Although a recent metaanalysis found no strong statistical justification for increased aggressiveness or worse prognosis in human SS18-SSX1 tumors, 25 our more detailed analysis of all the available human series confirmed that male hosts and BSS histology are specifically rare in the SS18-SSX2 genotype. In our direct comparison in mice, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1 (and equal between genders) and generated BSS histology equivalently. Therefore, these represented two genotype-phenotype relationships in human synovial sarcoma that expression of each fusion in mice failed to recapitulate. Each demanded explanation.
Each may derive purely from species differences between mouse and human. However, dismissal of these as species-specific modeling failures does not acknowledge one critical character of each departure. In the mouse, SS18-SSX2 drives more-not lessof synovial sarcoma biology than is apparent from human tumor epidemiology. In mice, there is no large sub-population of males that do not develop tumors. There is no failure to develop the quintessential synovial sarcoma biology that reprograms mesenchymal cells to organize into the epithelial mucinous glandular structures of BSS histology. The model fails only to limit or partly block each of these biologies as is apparent in human SS18-SSX2 tumor epidemiology. Rather than speciesspecific differences in the response to each fusion genotype, therefore, it may relate instead to other artifacts of the model, particularly that expression of a cDNA of the fusion oncogene produced by a chromosomal translocation does not model the other genetic and epigenetic effects of the translocation on the genes near the translocated locus.
This alternate hypothesis that emphasizes the translocation locus effects was supported by the fact that SSX gene expression is almost the only differential expression between the two human tumor genotypes that is maintained across multiple patient series. It is also supported by the demonstration that human tumors almost universally express native SSX2 in addition to the fusion and that SS18-SSX1 tumors express more SSX2 than tumors of the SS18-SSX2 fusion genotype. The fact that both tumorigenesis and BSS histology seem to be limited more profoundly in males also fits with an effect mediated by loss of native SSX2, on the X chromosome.
Generally, X-linkage is considered only in germline heritable traits, because of inactivation of one X chromosome in each female somatic cell. Three points prompt its consideration in this somatic disorder: (1) the inactive X chromosome in a female cell could be involved in the translocation itself. (2) Many genes on the inactive X chromosome in any female somatic cell are still expressed, escaping imprinting. 37 (3) The SSX genes are cancer/ testis antigens, only expressed normally in the testis and remaining epigenetically silenced in all other cells unless pathologically activated in certain cancers. 7, 8 Thus, whether residing on an active or inactive X chromosome, the SSX loci must be epigenetically reactivated to be expressed in a cancer arising outside the testis. A female cell will have two copies of each SSX locus physically available for such reactivation. As SSX2B, a locus in opposite orientation but on the same arm of the X chromosome ( Supplementary Figure 3c) , codes for the same protein as SSX2, female cells will have three copies and male cells will have one copy of the coding sequence available after the translocation that generates SS18-SSX2. The existence of SSX2B may explain the incomplete/subtle X-linkage of SSX2, evidenced by the non-zero prevalence of males with SS18-SSX2 tumors, generally, and even biphasic tumors in some series.
Demonstrating that modulation of SSX2 levels impacts proliferation in human synovial sarcoma cell lines suggests that SSX2 may function as an oncogene. Such a role has been demonstrated in other cancers, such as breast cancer, melanoma and osteosarcoma. 38, 39 Certainly, prospective experiments are warranted, as the capacity to generate translocations and assay transformation and tumorgenesis from them in normal human cells in vitro are developed.
A role for native SSX2 in the de novo gland formation that is characteristic of BSS histology in synovial sarcomas will be even more difficult to test experimentally. Identification of RAB3IP as not only among, but most significant within, the small group of genes differentially expressed consistently between three comparisons of BSS with MSS histology in human synovial sarcomas, was surprising. The SSX2 protein pulled down RAB3IP specifically in a yeast two-hybrid assay, whereas SSX1 did not. 40 The described interaction domain is in the portion of SSX2 not included in the fusion oncoprotein. A guanine exchange factor for RAB8, the protein encoded by the RAB3IP gene, often called Rabin8, has been shown to be important in gland initiation and ciliogenesis. [41] [42] [43] How SSX2 may impact these functions remains to be investigated once models are available.
We have therefore shown in mice that both SS18-SSX1 and SS18-SSX2 are capable of independently driving synovial sarcomagenesis. Insofar as these models test the impact of each fusion oncogene alone, we find no important tumor phenotypic differences. The differences we confirm epidemiologically in human tumors of the SS18-SSX2 translocation genotype, we hypothesize to be related to the translocation locus rather than the fusion gene generated.
MATERIALS AND METHODS
A Supplementary detailed methods section presents more specifics on each method utilized.
Study design
Experimental designs were controlled laboratory experiments or depended on either data already collected or specimens already collected and previously reported and indicated. The only randomization used was in manipulations applied to wells of cultured cells, which was done systematically, without any opportunity for bias. Individuals assessing outcomes of histology or cell counts were always blinded as to the group assignment of the specimen being analyzed. Sample size was not precalculated by power analysis as the inputs of sample variance were not known a priori for most experiments. For other experiments, there was a limited sample size available as subjects from the reported literature, such as in Table 1 . Series were excluded from that analysis if gender data or SS18-SSX genotype data was not reported and was not retrievable from the original corresponding authors. Otherwise, all data were included from each experiment reported. Outlier data points were not excluded from any analysis. Replicates for each cell line experiment are noted in the figure legends. Blinding was used for all assessments that included the potential for bias on the part of the assessor, such as histology and imaging.
Mice
All mouse work was performed with the approval of the institutional animal care and use committee and in accordance with international legal and ethical norms. The mice bearing Rosa26-targeted conditional SS18-SSX2, were previously described, 16 as were Rosa26-CreER, 44 Myf5-Cre 16 and Hprt-Cre 45 mice. The full-length cDNA of SS18-SSX1 was reverse transcribed from total RNA isolated from a human synovial sarcoma sample procured with approval of the institutional review board. Primers were identical to SS18-SSX1 and SS18-SSX2 in synovial sarcomagenesis those used for the prior isolation of SS18-SSX2. 16 In all cases, mouse strains were maintained on a mixed C57BL/6 and SvJ background. Littermates were used for comparison controls, whenever possible. The sex of animals was equivalently male and female and not intentionally varied in any group.
Whole-exome sequencing
Libraries were prepared using the Sure Select Mouse All Exon kit (Agilent Technologies, Santa Clara, CA, USA) for exome enrichment. Paired 
Clinical series
We retrieved the raw data from 17 of the largest clinical series of human synovial sarcomas in which the fusion type was identified by RT-PCR. 20-24,46-57 Figure 6 . Human SS18-SSX1 and SS18-SSX2 synovial sarcomas differentially express SSX genes. (a) Venn diagram of differentially expressed genes (t-test P o0.05) shared between three groups of human synovial sarcomas previously profiled by cDNA microarray. (b) Cluster heatmap of one group of samples and all probes for the seven genes differentially expressed in all three groups. (*indicates P-valueo0.5 differences between expression in the two tumor genotypes that was shared by the other samples in significance and direction of change). (c) Gel image demonstrating RT-qPCR to determine the presence of each fusion gene in 23 human synovial sarcoma samples, over the corresponding plot of RT-qPCR GAPDH-normalized fold-change expression levels (relative to SSX1 in testis) of native SSX2 (triangles) and SSX1 (circles), with cyan representing SS18-SSX1 tumors and magenta SS18-SSX2 tumors). Sample 9 demonstrated neither SS18-SSX1 nor SS18-SSX2 expression. Sample 20 (annotated below with an additional male symbol), the only SS18-SSX2 tumor from a male, was also the only tumor with negligible native SSX2 expression. (d) Mean ± s.e.m. of the RT-qPCR-determined SSX2 expression for each human tumor fusion genotype. P-value is from twotailed Student's t-test.
With the approval of the institutional review board at the University of Utah and in accordance within all international legal and ethical standards, tissue samples from histologically and molecularly confirmed synovial sarcoma patients were procured after obtaining informed consent.
Expression data
Raw data from Gene Expression Omnibus accession GSE20196 and GSE54187 were downloaded and analyzed using DChip software. 58 SS18-SSX1 and SS18-SSX2 in synovial sarcomagenesis
